Literature DB >> 19857603

Fatty liver and lipotoxicity.

Michael Trauner1, Marco Arrese, Martin Wagner.   

Abstract

Fatty liver disease comprises a spectrum ranging from simple steatosis to steatohepatitis which can progress to liver cirrhosis and hepatocellular cancer. Hepatic lipotoxicity may ensue when the hepatic capacity to utilize, store and export fatty acids (FA) as triglycerides is overwhelmed. Additional mechanisms of hepatic lipotoxicity include abnormal FA oxidation with formation of reactive oxygen species, disturbances in cellular membrane FA and phospholipid composition, alterations of cholesterol content and ceramide signalling. Lipotoxicity is a key factor for the progression of fatty liver disease by inducing hepatocellular death, activating Kupffer cells and an inflammatory response, impairing hepatic insulin signalling resulting in insulin resistance, and activation of a fibrogenic response in hepatic stellate cells that can ultimately lead to cirrhosis. Therefore, the concept of hepatic lipotoxicity should be considered in future therapeutic concepts for fatty liver disease. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857603     DOI: 10.1016/j.bbalip.2009.10.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  94 in total

1.  Two polymorphisms of USF1 gene (-202G>A and -844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case-control study in Chinese Han population.

Authors:  Xu Zhou; Hua-qiang Zhu; Chao-qun Ma; Hong-guang Li; Fang-feng Liu; Hong Chang; Jun Lu
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

2.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

3.  Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus.

Authors:  Marco Arrese
Journal:  Nat Rev Endocrinol       Date:  2010-12       Impact factor: 43.330

Review 4.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

5.  Free Fatty Acids Increase Intracellular Lipid Accumulation and Oxidative Stress by Modulating PPARα and SREBP-1c in L-02 Cells.

Authors:  Shumin Qin; Jinjin Yin; Keer Huang
Journal:  Lipids       Date:  2016-06-07       Impact factor: 1.880

6.  Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway.

Authors:  I-Pin Chou; Yuan Yu Lin; Shih-Torng Ding; Ching-Yi Chen
Journal:  Eur J Nutr       Date:  2013-10-16       Impact factor: 5.614

7.  Moro orange juice prevents fatty liver in mice.

Authors:  Federico Salamone; Giovanni Li Volti; Lucilla Titta; Lidia Puzzo; Ignazio Barbagallo; Francesco La Delia; Shira Zelber-Sagi; Michele Malaguarnera; Pier Giuseppe Pelicci; Marco Giorgio; Fabio Galvano
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

8.  Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice.

Authors:  Theodore C Friedman; Indrani Sinha-Hikim; Meher Parveen; Sonia M Najjar; Yanjun Liu; Michael Mangubat; Chang-Sung Shin; Alexei Lyzlov; Rasheed Ivey; Magda Shaheen; Samuel W French; Amiya P Sinha-Hikim
Journal:  Endocrinology       Date:  2012-10-23       Impact factor: 4.736

9.  Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.

Authors:  Pablo Quintero; Margarita Pizarro; Nancy Solís; Juan Pablo Arab; Oslando Padilla; Arnoldo Riquelme; Marco Arrese
Journal:  J Physiol Biochem       Date:  2014-05-10       Impact factor: 4.158

10.  Increased lipid synthesis and decreased β-oxidation in the liver of SHR/NDmcr-cp (cp/cp) rats, an animal model of metabolic syndrome.

Authors:  Shizuyo Tanaka; Tohru Yamazaki; Satoshi Asano; Atsushi Mitsumoto; Daisuke Kobayashi; Naomi Kudo; Yoichi Kawashima
Journal:  Lipids       Date:  2013-09-18       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.